New York, NY,
09
November
2021
|
10:00 AM
America/New_York

HSS Study Sheds Light on Real-World Treatment Patterns of Psoriatic Arthritis

Despite clear directives outlined in the updated guidelines published by the American College of Rheumatology/National Psoriasis Foundation (ACR/NPF) in 2018, there is limited data regarding medication use in real-world clinical practice and patient medication preferences for the treatment of psoriatic arthritis (PsA).

According to a new study conducted by researchers at Hospital for Special Surgery (HSS) in New York City and presented at the ACR annual meeting, there has been a significant increase in anti-IL17 and anti-phosphodiesterase-4 (anti-PDE4) medications being used as initial treatment for PsA since 2018, which may reflect their inclusion as potential initial therapy in the ACR/NPF guidelines, as well as the importance placed by patients on medication side effects.

“Regarding patient medication preferences, we found patients highly value preservation of their joint and function as well as safety,” said lead study author Monica Schwartzman, MD, MS, a rheumatologist at HSS. “We can use these findings to help us tailor our therapy to achieve the best outcomes for our patients.”

PsA is a very heterogenous disease with five distinct patterns of arthritis, which can make it challenging to treat. The disease is associated with a myriad of extra articular manifestations, including skin psoriasis, uveitis, and enthesitis, as well as comorbidities such as metabolic syndrome and depression.

The investigators sent surveys to patients in the HSS PsA registry. Preferences were ranked on a five-point Likert scale ranging from “not at all important” to “extremely important.” The median age of the 137 respondents was 60 years, and the median duration of PsA skin symptoms, joint symptoms, and PsA diagnosis by a physician was 19, 12, and 8 years respectively.

The survey solicited information regarding phenotypic features and characteristics of the respondent’s PsA, demographics, initial and current therapy, and medication preferences. Preference domains included medication efficacy for skin and joint disease, time to onset of efficacy, mode and frequency of administration, cost and insurance coverage, need for laboratory monitoring, side-effect profile, ability to affect function, and advice from physicians, peers, or commercial entities.

The researchers found that 62% of patients were first treated with non-steroidal anti-inflammatory drugs (NSAIDs). The most common initial immunomodulatory medications were anti-tumor necrosis factor (TNF)-α (35%), followed by methotrexate (19%), anti-PDE4 (12.4%), other conventional synthetic disease modifying anti-rheumatic medications (csDMARDs) (11.7%), anti-IL17 (5.1%), and anti-IL23 (2.9%). At survey administration, the most common immunomodulatory therapies were anti-TNF-α (30%), followed by anti-IL17 (20.4%), methotrexate (10.2%), anti-PDE4 (8.8%), other csDMARDs (8.0%), Janus kinase inhibitors (2.2%), and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA 4) (1.5%), while 28% of patients were not on any immunomodulatory therapy. Following the publication of the 2018 ACR/NPF updated guidelines for PsA, a significantly higher percentage of patients’ first medications was an anti-IL17 compared to 2018 or earlier (30% vs 3.5% P<0.001). This pattern was also seen with anti-PDE4 medications (40% vs 11.5% P<0.012).

Medication preferences most respondents ranked as “extremely important” were prevention of joint damage (80%), ability to perform daily activities (71%), prevention of pain (70%), rheumatologist recommendation (63%), and medication side effects (62%).

“At HSS, more patients with PsA are being started on an anti-TNF before methotrexate. This likely reflects the fact that many of these patients have axial disease that methotrexate cannot treat effectively,” said Lisa A. Mandl, MD, MPH, a rheumatologist at HSS and a study coauthor. “Patients with PsA, who are often younger, are telling us they want to be treated with medication which will keep them mobile and active. It is important to take into consideration when making therapeutic decisions that alleviating pain is not the only concern. Medications like NSAIDs, which may be effective for pain relief, are not aligned with patient’s long-term goals, as they are not an effective disease-modifying agent.”

Dr. Schwartzman said the 2018 guidelines on PsA from the ACR/NPF support a wider range of medications as initial therapy. “Over the last decade or so, our treatment armamentarium has expanded in an incredible way for this disease, and it includes medications with novel mechanisms of action.” She added the increasing use of newer agents with novel mechanisms of action may “indicate a therapeutic need unfulfilled by traditional medications.”

The researchers say more research is needed on the 28% of patients who were not receiving any immunomodulatory therapy. Left untreated, PsA can lead to functional impairment, poor quality of life, and significant morbidity and mortality.

About HSS

HSS is the world’s leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the 12th consecutive year), No. 4 in rheumatology by U.S. News & World Report (2021-2022), and the best pediatric orthopedic hospital in NY, NJ and CT by U.S. News & World Report “Best Children’s Hospitals” list (2021-2022). HSS is ranked world #1 in orthopedics by Newsweek (2021-2022). Founded in 1863, the Hospital has the lowest complication and readmission rates in the nation for orthopedics, and among the lowest infection rates. HSS was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center five consecutive times. The global standard total knee replacement was developed at HSS in 1969. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State, as well as in Florida. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. The HSS Global Innovation Institute was formed in 2016 to realize the potential of new drugs, therapeutics and devices. The HSS Education Institute is a trusted leader in advancing musculoskeletal knowledge and research for physicians, nurses, allied health professionals, academic trainees, and consumers in more than 130 countries. The institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally. www.hss.edu.